Sector News

Beigene expands into cancer cell therapy with Shoreline pact

June 13, 2021
Life sciences

Beigene has quickly become a force in cancer drug development, earning approvals in the U.S. and China for its targeted therapy Brukinsa and immunotherapy tislelizumab. The biotech is developing a slate of small molecule and antibody drugs aimed at several well-known targets, too.

In late 2019, Amgen agreed to pay nearly $3 billion for a 20% stake in Beigene. Notably, Beigene agreed to help Amgen develop as many as 20 experimental drugs and chip in funding as well, a sign of Amgen’s confidence in the company’s research skills.

So far, all of the drugs Beigene has advanced into clinical testing have been small molecules or antibodies. The Shoreline deal will expand the company’s work to include cell therapy, an area that’s growing quickly to encompass multiple types of treatment and technologies. READ MORE

By Ned Pagliarulo

Source: biopharmadive.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).